The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice

Transplant Immunology

Volumn 19, Issue 3-4, 2008, Pages 192-196

  Wang, Jian ^a   Figurski, Michael ^b   Shaw, Leslie M ^b   Burckart, Gilbert J ^c  

^a University of Southern California ^*  (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cyclosporine; Knockout mouse; mdr1; Mrp2; Mycophenolic acid; P glycoprotein

Indexed keywords

CYCLOSPORIN A; DRUG METABOLITE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADOLESCENT; ANIMAL EXPERIMENT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG METABOLISM; DRUG PROTEIN BINDING; IMMUNOSUPPRESSIVE TREATMENT; MALE; MONOTHERAPY; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; GLUCURONIDES; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYCOPHENOLIC ACID; P-GLYCOPROTEIN;

EID: 48149098366     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2008.05.009     Document Type: Article

References (36)

1. Allison A.C., and Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 (2000) 85-118
2. Fulton B., and Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51 (1996) 278-298
3. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353 (2005) 2219-2228
4. Staatz C.E., and Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46 (2007) 13-58
5. Westley I.S., Brogan L.R., Morris R.G., Evans A.M., and Sallustio B.C. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos 34 (2006) 261-266
6. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84 (1987) 7735-7738
7. Konig J., Nies A.T., Cui Y., Leier I., and Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461 (1999) 377-394
8. Lim S.W., Li C., Sun B.K., Han K.H., Kim W.Y., Oh Y.W., et al. Long-term treatment with cyclosporine decreases aquaporins and urea transporters in the rat kidney. Am J Physiol Renal Physiol 287 (2004) F139-F151
9. Elamiri A., Perwaiz S., Tuchweber B., and Yousef I.M. Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice. Pharmacol Res 48 (2003) 467-472
10. Hesselink D.A., van Schaik R.H., van der Heiden I.P., van der Werf M., Gregoor P.J., Lindemans J., et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74 (2003) 245-254
11. Pou L., Brunet M., Cantarell C., Vidal E., Oppenheimer F., Monforte V., et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit 23 (2001) 35-38
12. Kobayashi M., Saitoh H., Kobayashi M., Tadano K., Takahashi Y., and Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 309 (2004) 1029-1035
13. van Gelder T., Klupp J., Barten M.J., Christians U., and Morris R.E. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23 (2001) 119-128
14. Van Gelder T., Klupp J., Barten M.J., Christians U., and Morris R.E. Co-administration of tacrolimus and mycophenolate mofetil does not increase mycophenolic acid (MPA) exposure, but co-administration of cyclosporine inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure. J Heart Lung Transplant 20 (2001) 160-161
15. Kamisako T., Leier I., Cui Y., Konig J., Buchholz U., Hummel-Eisenbeiss J., et al. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology 30 (1999) 485-490
16. Hale M.D., Nicholls A.J., Bullingham R.E., Hene R., Hoitsma A., Squifflet J.P., et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 64 (1998) 672-683
17. Figurski M.J., Korecka M., Fields L., Waligórska T., and Shaw L.M. HPLC-MS/MS method for simultaneous quantification of total or free fraction of mycophenolic acid and its glucuronide metabolites. Ther Drug Monit 29 (2007) 511-512
18. Naesens M., Kuypers D.R., Verbeke K., and Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82 (2006) 1074-1084
19. Satoh S., Tada H., Murakami M., Tsuchiya N., Li Z., Numakura K., et al. Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 82 (2006) 486-493
20. Levesque E., Delage R., Benoit-Biancamano M.O., Caron P., Bernard O., Couture F., et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 81 (2007) 392-400
21. Naesens M., Kuypers D.R., Streit F., Armstrong V.W., Oellerich M., Verbeke K., et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther 80 (2006) 509-521
22. Figurski M.J., KM, Fields L., Waligórska T., and Shaw L.M. HPLC-MS/MS method for simultaneous quantification of total or free fraction of mycophenolic Acid and its glucuronide metabolites. Ther Drug Monit 29 (2007) 511-512
23. Westley I.S., Morris R.G., Evans A.M., and Sallustio B.C. Glucuronidation of mycophenolic acid by Wistar and Mrp2-deficient TR-rat liver microsomes. Drug Metab Dispos 36 (2008) 46-50
24. Mancinelli L.M., Frassetto L., Floren L.C., Dressler D., Carrier S., Bekersky I., et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 69 (2001) 24-31
25. Kaplan B., Lown K., Craig R., Abecassis M., Kaufman D., Leventhal J., et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation 67 (1999) 333-3335
26. Bullingham R., Monroe S., Nicholls A., and Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36 (1996) 315-324
27. Pescovitz M.D., Conti D., Dunn J., Gonwa T., Halloran P., Sollinger H., et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant 14 (2000) 179-188
28. Nowak I., and Shaw L.M. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 41 (1995) 1011-1017
29. Chandra P., and Brouwer K.L. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 21 (2004) 719-735
30. Hirohashi T., Suzuki H., Ito K., Ogawa K., Kume K., Shimizu T., et al. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats. Mol Pharmacol 53 (1998) 1068-1075
31. Ogawa K., Suzuki H., Hirohashi T., Ishikawa T., Meier P.J., Hirose K., et al. Characterization of inducible nature of MRP3 in rat liver. Am J Physiol Gastrointest Liver Physiol 278 (2000) G438-G446
32. Konig J., Rost D., Cui Y., and Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29 (1999) 1156-1163
33. Johnson B.M., Zhang P., Schuetz J.D., and Brouwer K.L. Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab Dispos 34 (2006) 556-562
34. Vlaming M.L., Mohrmann K., Wagenaar E., de Waart D.R., Elferink R.P., Lagas J.S., et al. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318 (2006) 319-327
35. Chu X.Y., Strauss J.R., Mariano M.A., Li J., Newton D.J., Cai X., et al. Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J Pharmacol Exp Ther 317 (2006) 579-589
36. Bullingham R.E., Nicholls A., and Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 28 (1996) 925-929